Retinitis Pigmentosa Clinical Trial
Official title:
A Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa Associated With NR2E3 and RHO Mutations and Leber Congenital Amaurosis With Mutation(s) in CEP290 Gene
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects Investigators will also conduct a Natural History Study (OCU400-104)i This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 24 subjects in the OCU400-101 and 100 subjects in the OCU400-104 study.
Status | Recruiting |
Enrollment | 124 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years and older |
Eligibility | Diagnosis and main criteria for inclusion: Subjects meeting all inclusion criteria and none of the exclusion criteria are eligible for study participation. Inclusion Criteria for Adult RP 1. Males or females =18 years of age at the time of informed consent. 2. Confirmed genetic diagnosis of biallelic autosomal recessive NR2E3 mutations or autosomal dominant NR2E3 mutation for Subgroup 1 or autosomal dominant RHO mutations for Subgroup 2. 3. For subjects in Cohort 1-3, BCVA = 20/50 or visual field less than 20° in any meridian, as measured by a III4e isopter or equivalent in study eye. 4. Unable to perform a Multi-Luminance Mobility Testing (MLMT) using study eye at 1 lux, the lowest luminance level tested. Exclusion Criteria for Adult RP 1. Subject lacks evidence of outer nuclear layer 2. Considered unsuitable for any reason that may either place the subject at increased risk during participation or interfere with the interpretation of the study outcomes by the Investigator, or the Sponsor after reviewing medical, ocular, and psychiatric history, clinical examination, and laboratory evaluation, as determined by the Investigator 3. Previous treatment with a gene-therapy or cell therapy product. 4. Previous treatment with any investigational drug or device within one year. 5. Any contraindications for subretinal injection. Inclusion Criteria for Adult LCA 1. Males or females at least 18 years of age at the time of informed consent. 2. Clinical diagnosis of LCA and confirmed genetic diagnosis of CEP290 mutation. 3. Best corrected visual acuity (BCVA) equal to or worse than LogMAR +0.7 but equal to or better than LogMAR 3.5 (light perception) in the study eye. 4. Detectable outer nuclear layer in the macular region as determined by spectral-domain optical coherence tomography (SD-OCT). Exclusion Criteria for Adult LCA 1. Any symptom of central nervous system involvement/disease that would impact the ability to measure visual function 2. Any contraindications for subretinal injection. 3. Any intraocular surgery within 6 months. 4. Active ocular/intraocular infection (e.g., conjunctivitis, keratitis, scleritis, endophthalmitis) Inclusion Criteria for Pediatric RP 1. Males or females 6 - 17 years of age (inclusive) at the time of parental permission and/or assent, whichever is applicable. 2. Confirmed genetic diagnosis of biallelic autosomal recessive NR2E3 mutations or autosomal dominant NR2E3 mutation for Subgroup 1 or autosomal dominant RHO mutations for Subgroup 2. 3. BCVA = 20/32 or visual field less than 20° in any meridian, as measured by a III4e isopter or equivalent in study eye. 4. Able to perform a Multi-Luminance Mobility Testing (MLMT) using study eye, but unable to pass the MLMT at 1 lux, the lowest luminance level tested. Exclusion Criteria for Pediatric RP 1. Subject lacks evidence of outer nuclear layer as determined by spectral-domain optical coherence tomography (SD-OCT). 2. Previous treatment with a gene-therapy or cell therapy product. 3. Previous treatment with any investigational drug or device within one year. 4. Any contraindications for subretinal injection. 5. Breast-feeding, pregnancy, or inability to practice strict contraception within the Treatment Observation Period for subjects of childbearing potential. 6. Active ocular/intraocular infection (e.g., conjunctivitis, keratitis, scleritis, endophthalmitis) Inclusion Criteria for Pediatric LCA 1. Males or females 6 - 17 years of age (inclusive) at the time of parental permission and/or assent, whichever is applicable. 2. Clinical diagnosis of LCA and confirmed genetic diagnosis of CEP290 mutation. 3. Best corrected visual acuity (BCVA) equal to or worse than LogMAR +0.7 but equal to or better than LogMAR 3.5 (light perception) in the study eye. 4. Detectable outer nuclear layer in the macular region as determined by spectral-domain optical coherence tomography (SD-OCT). Exclusion Criteria for Pediatric LCA 1. Any symptom of central nervous system involvement/disease that would impact the ability to measure visual function 2. Any contraindications for subretinal injection. 3. Active ocular/intraocular infection (e.g., conjunctivitis, keratitis, scleritis, endophthalmitis) 4. Breast-feeding, pregnancy, or inability to practice strict contraception within the Treatment Observation Period for subjects of childbearing potential. |
Country | Name | City | State |
---|---|---|---|
United States | Ocugen Site 6 - Emory University | Atlanta | Georgia |
United States | Ocugen Site 1 - Retina Foundation of the Southwest | Dallas | Texas |
United States | Ocugen Site 5 - University of California, San Diego (UCSD) - Shiley Eye Institute | La Jolla | California |
United States | Ocugen Site 3 - Bascom Palmer Eye Institute | Miami | Florida |
United States | Ocugen Site 8 - Mid Atlantic Retina - Wills Eye Hospital | Philadelphia | Pennsylvania |
United States | Associated Retina Consultants | Phoenix | Arizona |
United States | Ocugen Site 2 - Casey Eye Institute - OHSU | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
Ocugen |
United States,
Li S, Datta S, Brabbit E, Love Z, Woytowicz V, Flattery K, Capri J, Yao K, Wu S, Imboden M, Upadhyay A, Arumugham R, Thoreson WB, DeAngelis MM, Haider NB. Nr2e3 is a genetic modifier that rescues retinal degeneration and promotes homeostasis in multiple models of retinitis pigmentosa. Gene Ther. 2021 May;28(5):223-241. doi: 10.1038/s41434-020-0134-z. Epub 2020 Mar 2. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Multi-luminance mobility testing (MLMT) | Subjects will navigate a standardized mobility maze under set conditions as specified times during the study. The mobility testing will follow a standardized administration and data acquisition protocol and may only be administered by site staff certified in the methodology. | 1 year (Changes from baseline) | |
Other | Changes in ellipsoid zone width/length on wide-field 45° SD-OCT | Ellipsoid zone area/outer segment length will be determined by Spectral Domain Optical Coherence Tomography (SD-OCT) using standardized systems and acquisition protocols. | 1 year (Changes from baseline) | |
Other | Contrast sensitivity | Contrast sensitivity will be conducted using Pelli-Robson chart. | 1 year (Changes from baseline) | |
Other | Full Field Light Stimulation Threshold (FST) | FST will be completed at scheduled times throughout the study period | 1 year (Changes from baseline) | |
Other | Static Visual Fields | The Octopus 900 will be used with a standardized white-on-white full field and a blue-on-yellow with full field | 1 year (Changes from baseline) | |
Other | Vision on Quality of Life | The National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ25) and the Michigan Retinal Degeneration Questionnaire (MRDQ) questionnaires will be administered to assess the impact of vision on quality of subject's life. | 1 year (Changes from baseline) | |
Other | Full Field Electroretinogram | The International Society for Clinical Electrophysiology of Vision (ISCEV) guidelines will be followed for conducting ff-ERG (Full-field Electroretinography) | 1 year (Changes from baseline) | |
Other | Wide-field fundus autofluorescence (wf-FAF) | The intensity of FAF will be evaluated using 55° posterior pole scanning. | 1 year (Changes from baseline) | |
Primary | Study Drug-related adverse events (SDAE) | Counts, frequencies and percentages of SDAEs. SDAE is a primary adverse event of interest and defined as AEs and SAEs that are direct subjects to the Study Drug only. | 1 year | |
Primary | Treatment-Emergent adverse events (TEAEs) | Counts, frequencies and percentages TEAEs. TEAEs are defined as an event that was not present prior to administration of the dose of study drug and present after the dose, or if it represents the exacerbation of an event that was present prior to the dose. | 1 year | |
Primary | Serious adverse events (SAEs) | Counts, frequencies and percentages of SAEs including Resulted in Death, Life-threatening, Hospitalization, Disabling/incapacitating, Congenital anomaly or birth defect and Medically significant AEs ( AE that did not meet any of the above criteria but could have jeopardized the subject and might have required medical or surgical intervention to prevent one of the outcomes listed above). | 1 year | |
Secondary | Best-corrected visual acuity (BCVA) | Measured as the ETDRS letter score on the EVA tester or E-ETDRS charts. Electronic ETDRS Visual Acuity Testing Protocol will be followed (confidential). | 1 year (Changes from baseline) | |
Secondary | Low-luminance visual acuity (LLVA) | Electronic Visual Acuity Tester (EVA) and a Sponsor specific Low-Luminance lens will be used. Early Treatment of Diabetic Retinopathy Study (ETDRS) will also be accepted as a backup. | 1 year (Changes from baseline) | |
Secondary | Slit-lamp biomicroscopy | Changes in visual function. | 1 year (Changes from baseline) | |
Secondary | Intraocular pressure (IOP) | IOP measurement by applanation or rebound tonometry. Confirmation with Goldmann tonometer if IOP reading is outside the normal range (8-21mmHg). | 1 year (Changes from baseline) | |
Secondary | Indirect ophthalmoscopy | If visual acuity is so poor that the participant is unable to count fingers or perceive hand motion, light perception will be tested with the indirect ophthalmoscope as the light source. | 1 year (Changes from baseline) | |
Secondary | anti-AAV5 (anti Adeno-associated virus type 5) | Blood samples will be collected for the assessment. These samples will be analyzed using validated assays at a bioanalytical laboratory. | 1 year | |
Secondary | anti-hNR2E3 antibodies (hNR2E3 gene) | Blood samples will be collected for the assessment. These samples will be analyzed using validated assays at a bioanalytical laboratory. | 1 year | |
Secondary | T-cell response | Blood samples will be collected for the assessment. These samples will be analyzed using validated assays at a bioanalytical laboratory. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
Completed |
NCT04983914 -
Retrospective NIS to Evaluate the Patient Benefit of TES
|
||
Recruiting |
NCT03845218 -
Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
|
||
Completed |
NCT00231010 -
Molecular Genetics of Retinal Degenerations
|
||
Active, not recruiting |
NCT04611503 -
PDE6A Gene Therapy for Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Recruiting |
NCT01914913 -
Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Completed |
NCT01949623 -
Biomarkers In Retinitis Pigmentosa (BIRP)
|
N/A | |
Completed |
NCT01835002 -
Transcorneal Electrical Stimulation - Multicenter Safety Study
|
N/A | |
Completed |
NCT00407602 -
Argus® II Retinal Stimulation System Feasibility Protocol
|
N/A | |
Completed |
NCT00515814 -
Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors
|
N/A | |
Completed |
NCT00100230 -
DHA and X-Linked Retinitis Pigmentosa
|
Phase 2 | |
Active, not recruiting |
NCT00378742 -
Repository for Inherited Eye Diseases
|
||
Terminated |
NCT05085964 -
An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
|
Phase 2 | |
Recruiting |
NCT05805007 -
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
|
Early Phase 1 | |
Recruiting |
NCT06291935 -
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
|
Phase 1 | |
Recruiting |
NCT05909488 -
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
|
Phase 2/Phase 3 | |
Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
Completed |
NCT04238858 -
Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa
|
N/A | |
Active, not recruiting |
NCT01680510 -
The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil
|
Phase 1/Phase 2 |